The predictive power of the FFL (PDGF/FLT1/SHC1) in the PIK3CA-mutated luminal-A tumor patients demonstrated in this study could be further validated in other breast cancer cohorts when genome sequencing data for these cohorts are available in the future. This evidence concerns the gene PIK3CA and neoplasm.